{"id":"W2479313949","doi":"10.1200/jco.2016.34.4_suppl.569","title":"Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; FOLFIRI; Bevacizumab; Irinotecan; Internal medicine; Adverse effect; Regimen; Neutropenia; Colorectal cancer; Mucositis; Oncology; Gastroenterology; Tolerability; Phases of clinical research; Febrile neutropenia; Combination therapy; Cancer; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009325031,0.001336094,0.002310395,0.0005357098,0.0004634676,0.0009601182,0.0007618041,0.00127534,0.002532205],"category_scores_gemma":[0.0006180401,0.0007839758,0.0009543243,0.000522819,0.001054878,0.0007408105,0.0003845184,0.002765925,0.0007843613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001113762,"about_ca_system_score_gemma":0.001727431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001813917,"about_ca_topic_score_gemma":0.003481301,"domain_scores_codex":[0.9995949,0.0001677108,0.00002519648,0.0000689432,0.00003706774,0.0001062903],"domain_scores_gemma":[0.999438,0.00006297709,0.0001089144,0.00004153542,0.00003309068,0.0003154701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6420587,0.1395184,0.007427248,0.0008268916,0.001260613,0.0004470453,0.0004743568,0.002888839,0.1310327,0.0002610626,0.002326336,0.07147785],"study_design_scores_gemma":[0.2339359,0.7448761,0.008884122,0.00002422902,0.0004750632,0.0003115827,0.00007999709,0.00105354,0.008590141,0.00009093839,0.001655313,0.00002310511],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956352,0.0009990749,0.0003740451,0.0002400672,0.00007561617,0.001384632,0.0003961163,0.00005599411,0.0008392511],"genre_scores_gemma":[0.9944146,0.0008281805,0.0009741911,0.0003304608,0.00009849797,0.00115121,0.0009713288,0.00001605281,0.001215374],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002532205,"threshold_uncertainty_score":0.008471072,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05698833011345561,"score_gpt":0.4185624933571529,"score_spread":0.3615741632436973,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}